共 58 条
[1]
Goldberg SB(2016)Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial Lancet Oncol 17 976-983
[2]
Gettinger SN(2012)Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Lancet Oncol 13 459-465
[3]
Mahajan A(2018)Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study Lancet Oncol 19 672-681
[4]
Margolin K(2020)Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial JAMA Oncol 5450 1024-205
[5]
Ernstoff MS(2016)PD-L1 expression and prognostic impact in glioblastoma Neuro Oncol 18 195-1075
[6]
Hamid O(2015)Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma Neuro Oncol 17 1064-2263
[7]
Long GV(2002)Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3) Eur J Immunol 32 2255-6
[8]
Atkinson V(2019)New emerging targets in cancer immunotherapy: the role of LAG3 ESMO Open 4 1-20
[9]
Lo S(2019)Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma Front Immunol 10 1-v612
[10]
Reardon DA(2017)Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched popu Ann Oncol 28 v611-3208